Literature DB >> 17180738

Use of the University of California Los Angeles Integrated Staging System (UISS) to predict survival in localized renal cell carcinoma in an Asian population.

Chi-Fai Ng1, Siu-Ho Wan, Annie Wong, Fernand M M Lai, Pun Hui, Chi-Wai Cheng.   

Abstract

OBJECTIVES: To evaluate the applicability of the University of California Los Angeles Integrated Staging System (UISS) in predicting the prognosis of Chinese patients with localized renal cell carcinoma after radical nephrectomy, with reference to that reported by Patard et al in an international multicenter study (J Clin Oncol 2004, 22:3316-3322).
METHODOLOGY: One hundred and twenty-eight Chinese patients with localized renal cell carcinoma were stratified into low risk (LR), intermediate risk (IR) and high risk (HR) groups according to the UISS, based on the TMN staging and Fuhrman grading of the tumor and the Eastern Cooperative Oncology Group performance status of the patients. The survival curves of each risk group were then calculated.
RESULTS: The number of patients in the LR, IR and HR was 24 (18.8%), 94 (73.4%) and 10 (7.8%) respectively. The estimated 2-year survival rates were 100%, 89.9% and 100% for the LR, IR and HR groups respectively. Whereas the estimated 5-year survival rates were 93.3%, 72.4% and 80% for the LR, IR and HR groups respectively. The LR and IR patients had comparable 2-year and 5-year estimated survival rates with those reported by Patard et al. However, the estimated survival rate for HR patients was better than that reported.
CONCLUSIONS: UISS provided a valuable tool in predicting the survival of Chinese patients with localized renal cell carcinoma of LR and IR groups, as reported in other international centers. Further large scale study may be needed to confirm the applicability in HR population.

Entities:  

Mesh:

Year:  2006        PMID: 17180738     DOI: 10.1007/s11255-006-9134-1

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  22 in total

1.  Current TNM classification of renal cell carcinoma evaluated: revising stage T3a.

Authors:  S Siemer; J Lehmann; A Loch; F Becker; U Stein; G Schneider; M Ziegler; M Stöckle
Journal:  J Urol       Date:  2005-01       Impact factor: 7.450

2.  A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma.

Authors:  Maximiliano Sorbellini; Michael W Kattan; Mark E Snyder; Victor Reuter; Robert Motzer; Manlio Goetzl; James McKiernan; Paul Russo
Journal:  J Urol       Date:  2005-01       Impact factor: 7.450

3.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

4.  Differences in treatment patterns for localized breast carcinoma among Asian/Pacific islander women.

Authors:  Angela W Prehn; Barbara Topol; Susan Stewart; Sally L Glaser; Lilia O'Connor; Dee W West
Journal:  Cancer       Date:  2002-12-01       Impact factor: 6.860

5.  Rising incidence of renal cell cancer in the United States.

Authors:  W H Chow; S S Devesa; J L Warren; J F Fraumeni
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

6.  Re-evaluation of the Tumour-Node-Metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a).

Authors:  Alana M Murphy; Scott M Gilbert; Aaron E Katz; Erik T Goluboff; Ihor S Sawczuk; Carl A Olsson; Mitchell C Benson; James M McKiernan
Journal:  BJU Int       Date:  2005-01       Impact factor: 5.588

7.  Comparison of bladder cancer survival among Japanese, Chinese, Filipino, Hawaiian and Caucasian populations in the United States.

Authors:  Mia Hashibe; Tie Gao; Gang Li; Guido Dalbagni; Zuo-Feng Zhang
Journal:  Asian Pac J Cancer Prev       Date:  2003 Jul-Sep

8.  External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma.

Authors:  Vincenzo Ficarra; Guido Martignoni; Christine Lohse; Giacomo Novara; Maurizio Pea; Stefano Cavalleri; Walter Artibani
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

Review 9.  Prognostic factors in renal cell carcinoma.

Authors:  James A Kontak; Steven C Campbell
Journal:  Urol Clin North Am       Date:  2003-08       Impact factor: 2.241

10.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

View more
  4 in total

Review 1.  Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.

Authors:  Sumanta Kumar Pal; Marcin Kortylewski; Hua Yu; Robert A Figlin
Journal:  Mol Cancer Ther       Date:  2010-11-15       Impact factor: 6.261

2.  Clinical symptoms related to renal cell carcinoma are independent prognostic factors for intraoperative complications and overall survival.

Authors:  Attila Szendroi; Adám Tabák; Peter Riesz; Miklós Szucs; Peter Nyírády; Attila Majoros; Gabriel Haas; Imre Romics
Journal:  Int Urol Nephrol       Date:  2009-03-13       Impact factor: 2.370

3.  High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear-Cell Renal Cell Carcinoma.

Authors:  Jianfeng Wang; Yunze Xu; Liangsong Zhu; Yun Zou; Wen Kong; Baijun Dong; Jiwei Huang; Yonghui Chen; Wei Xue; Yiran Huang; Jin Zhang
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

4.  High mucin 5AC expression predicts adverse postoperative recurrence and survival of patients with clear-cell renal cell carcinoma.

Authors:  Haijian Zhang; Yidong Liu; Huyang Xie; Weisi Liu; Qiang Fu; Dengfu Yao; Jiejie Xu; Jianxin Gu
Journal:  Oncotarget       Date:  2017-03-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.